Genotype and phenotype predictors in therapy response in renal cell carcinoma

描述（由申请人提供）：近年来，肾细胞癌（RCC）的治疗已通过靶向药物的疗效发生转变，靶向药物抑制参与关键细胞信号传导途径的激酶和VEGF（肿瘤血管生成的主要驱动因素）。然而，患者对这些疗法的反应是高度可变的，并且目前不能基于临床或病理学数据或可用的实验室/遗传检测来预测。该提案的目标是基于新的测试，为最常见的RCC亚型透明细胞（ccRCC）患者开发治疗反应的预测因子。我们的方法主要基于以下假设：ccRCC治疗中使用的靶向药物-贝伐单抗，舒尼替尼和索拉非尼-抑制肿瘤血管活化，并且肿瘤血管的活化状态和稳定性是反应的主要决定因素。我们还假设ccRCC肿瘤血管的表型与肿瘤细胞的分子病理学有关。特别是，由于这些药物也可以抑制肿瘤细胞信号传导并调节其行为，因此ccRCC肿瘤细胞信号传导、HIF-1/HIF-2（缺氧诱导因子）表达和VHL功能是反应的潜在决定因素。为了检查血管表型、肿瘤细胞表型和VHL基因型的参数作为治疗反应的预测因子，ccRCC标本将接受适当生物标志物抗原的多重免疫染色，并通过新型计算机辅助图像分析系统进行分析，该系统在细胞（细胞计数）基础上客观定量分析物染色以及传统的基于像素的分析。这些研究将在正在进行的多机构II期（ECOG 2804）和III期（ECOG 2805）临床试验中接受贝伐珠单抗、舒尼替尼或索拉非尼单药治疗的ccRCC患者的肿瘤中进行，使用来自90、170和170例适当ccRCC患者亚组的肿瘤块进行相应药物治疗。本提案的具体目的是（目的1）分析ccRCC肿瘤中的血管和内皮细胞活化表型和血管周细胞覆盖;（目的2）分析ccRCC肿瘤中的肿瘤细胞信号传导、HIF表型和VHL基因型;以及（目标3）使在先前目标中量化的参数相互关联，治疗结果，并开发简约的预测模型的治疗反应，使用生物统计学和生物信息学的方法。这些研究的结果应允许确定治疗ccRCC个体患者的最合适药物，并有助于合理开发二线和联合药物治疗。除了ccRCC之外，研究中的靶向药物用于治疗越来越多的癌症，并且为ccRCC开发的反应预测因子，其中这些药物由于作为单一药物使用而得到最好的研究，可能有助于预测这些其他癌症对合并靶向药物的联合治疗的反应。公共卫生相关性：新型靶向癌症治疗药物已成功治疗肾癌（肾细胞癌），这种癌症的发病率正在增加，每年有超过50，000名美国人被新诊断出。本项目的研究将描述肾细胞癌的肿瘤血管特征和遗传缺陷，并将其与治疗反应相关联，以确定可以预测其是否对治疗有反应的因素。发现预测治疗反应的肾癌特征，然后可以用于在未来对患者进行不同治疗 并将提供可能适用于用相同新药治疗的许多其他癌症的经验教训。

DESCRIPTION (provided by applicant): Therapy of renal cell carcinoma (RCC) has been transformed in recent years by the efficacy of targeted agents that inhibit kinases involved in critical cellular signaling pathways and VEGF, a primary driver of tumor angiogenesis. However, patient response to these therapeutics is highly variable and currently cannot be predicted based on clinical or pathological data or available laboratory/genetic testing. The goal of this proposal is to develop predictors of therapeutic response for patients with the most common subtype of RCC, clear cell (ccRCC), based on novel tests. Our approach is based primarily on the hypothesis that the targeted agents used in ccRCC therapy - bevacizumab, sunitinib and sorafenib - inhibit tumor vessel activation and that the activation status and stability of tumor vessels are major determinants of response. We also hypothesize that the phenotype of ccRCC tumor vessels is linked to the molecular pathobiology of the tumor cells. In particular, as these drugs also can inhibit tumor cell signaling and modulate their behavior, ccRCC tumor cell signaling, HIF-1/HIF-2 (hypoxia-inducible factor) expression and VHL function are potential determinants of response. To examine parameters of vascular phenotype, tumor cell phenotype and VHL genotype as predictors of response to therapy, ccRCC specimens will undergo multiplex immunostaining for the appropriate biomarker antigens and be analyzed by a novel computer-assisted image analysis system that objectively quantifies analyte staining on a cellular (cytometric) basis as well as by traditional pixel-based analysis. These studies will be performed on tumors of ccRCC patients treated with single-agent bevacizumab, sunitinib or sorafenib in ongoing multi-institutional phase II (ECOG2804) and phase III (ECOG2805) clinical trials, using tumor blocks from a subset of 90, 170 and 170 appropriate ccRCC patients for therapy with the respective drugs. The specific aims of this proposal are (Aim 1) to analyze the vascular and endothelial cell activation phenotype and vessel pericyte coverage in ccRCC tumors; (Aim 2) to analyze tumor cell signaling, HIF phenotype and VHL genotype in ccRCC tumors; and (Aim 3) to correlate parameters quantified in the prior aims for relationships to each other, to therapeutic outcome and to develop parsimonious predictive models of therapeutic response using biostatistical and bioinformatics approaches. The results of these studies should allow identification of the most appropriate drugs for treating individual patients with ccRCC and assist in the rational development of second-line and combination drug therapies. Beyond ccRCC, the targeted agents under study are used in the therapy of an ever expanding number of cancers, and the response predictors developed for ccRCC, where these agents are best studied because they are used as single-agents, may be useful for predicting response of these other cancers to combination therapy incorporating the targeted agents. PUBLIC HEALTH RELEVANCE: Novel targeted cancer therapy agents have shown success in the treatment of kidney cancer (renal cell carcinoma), a cancer that is increasing in incidence and newly diagnosed in over 50,000 Americans a year. Studies in this project will characterize the tumor blood vessel characteristics and genetic defect of renal cell carcinomas and correlate them with therapeutic response to identify factors that can predict whether they will respond to treatment. Discovering features of kidney cancer that predict therapeutic response can then be used to stratify patients to different therapies in the future and will provide lessons that are likely to be applicable to many other cancers being treated with the same novel drugs.